SPRO - Spero Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-7.816M

Cash

77.69M

Avg Qtr Burn

N/A

Short % of Float

3.88%

Insider Ownership

18.94%

Institutional Own.

27.24%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tebipenem HBr (previously SPR994): oral carbapenem Details Bacterial infection, Urinary tract infection	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SPR206 Details Bacterial infection, Lung disease	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SPR720 Details Bacterial infection, Lung disease	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.